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ABSTRACT
Preeclampsia (PE) have a high risk of pregnancy disorder and can cause liver and kidney disease. PE is a dangerous disease in Indonesia with a 
high risk of cardiovascular death. PE has biomarkers such as proteinuria, blood pressure, dipstick test, renin-angiotensin system, adipsin, calcium/
creatinine (Cr) ratio, albumin/Cr ratio, and uric acid. Apoptosis occurs in the placenta’s PE, where trophoblasts invade and overhaul the uterine 
spiral artery in the epidermal growth factor signaling system, and the expression of miRNA in PE is targeting genes in a variety of pathophysiological 
processes can cause kidney and hepatic disease. In this review, we will discuss role of HSP, miRNA, Immunology cell and the risk of kidney and hepatic 
disease of patient of Preeclampsia.
Keyword: Preeclampsia, Placenta, Kidney diseases, Hepatic diseases, mRNA.
INTRODUCTION
Preeclampsia (PE) is a dangerous and potentially life-threatening 
disease for the mother and fetus which occurs uniquely in Indonesia, 
so the improvement of the standard diagnostic approach with 
complement is very important for this problem and development 
of future treatment strategies [1,2]. According to Survei Demografi 
dan Kesehatan Indonesia in 2007, PE contributes to 24% of maternal 
mortality in Indonesia, makes it second cause of maternal death in 
Indonesia [3]. International non-governmental organization Forum on 
Indonesian Development states that Indonesia is a country in Southeast 
Asia with the highest maternal mortality of 359/100.000 births [4]. 
Chronic hypertension pre-pregnancy can lead to developmental rates 
of severe hypertension so that babies are premature and small [5]. One 
of the characteristics of PE is the syncytial node-forming process, the 
shedding of the syncytial aggregate, and the appearance of placental 
microparticles in the maternal and contributes to maternal vascular 
injury [6]. Strong evidence supports the involvement of deficient 
trophoblast survival, inadequate endovascular invasion, endothelial 
cell dysfunction, and a systemic maternal inflammatory response [7,8]. 
Failure of trophoblast invasion inhibits decidualization leading to poor 
placental blood supply in maternal vessels which further generates 
placental ischemia and apoptosis [9]. PE can cause diseases of the liver 
and kidneys. Those diseases may not be initiated by pregnancy, but 
interfere strongly with pregnancy. Exact diagnosis is therefore of high 
clinical relevance [10]. Not just in science, there is a direct and indirect 
relationship regarding the empowerment of PE prevention in pregnant 
women through the theory of social capital to Indonesia society [11].
BIOMARKER IN PE
PE may be characterized by hypertension and proteinuria after 20 weeks 
of pregnancy and a change in the angiogenic factor [12,13]. Detected 
proteinuria can be used dipstick test with urine sample concentration 
with creatinine (Cr) is higher [14]. Massive Urinary Protein also has the 
potential to be associated with more severe clinical manifestations of 
PE [15]. Significantly, isolated gestational (IG) proteinuria was also a 
risk factor for PE and IGP-PE accounted for most (20%) of all PE [16]. 
Women who have higher levels of urea nitrogen in the blood have a 
higher incidence of PE; premature labor (women with kidney disease 
with p<0.001), 8/35 (23%); premature rupture of membranes; and 
intrauterine growth restriction [17-19]. Urinary protein, adipsin, was 
found to increase significantly and the ratio of Cr to adipsin correlated 
with urine protein, for 24 h in 124 patients combined with elevated 
diastolic blood pressure (≥90 mm Hg) [20]. It is important to know 
that increased activity of a local renin–angiotensin system (RAS) in 
the kidney, correlates with high blood pressure, and proteinuria in 
PE [21]. Oral labetalol is more efficacious and important for effective 
control of blood pressure in PE [22]. Hypertension, proteinuria, and 
renal function resolved normally over an average period of 35.8 days 
and neurologic complications, pulmonary edema, and multiple organ 
failure can be a cause of death [23]. No woman with protein: Cr ratio 
<18 mg/mM (n=20) had significant proteinuria, but between 18 and 
60 mg/mM [24]. To assess the effectiveness of the calcium/creatinine 
ratio (CCR) as a diagnostic test for PE predicted, CCR at 0.04 in spot 
urine samples was a good test, as a screening test on all asymptomatic 
pregnant women [25]. The first albumin/creatinine ratio (ACR), for 
maternal and neonatal outcomes, is also an independent prognostic 
factor for maternal and fetal outcomes in suspected PE [26].
Proteinuria-onset PE is associated with an increased adverse risk of PE 
with the onset of hypertension [27]. Hypertension and proteinuria are 
very common outside the postpartum period in Cameroonian women 
with severe PE and eclampsia [28]. In severe PE with proteinuria >3 g/L 
showed that the amount of proteinuria is not associated with severe 
PE, although proteinuria is detected, prematurity may occur [29]. 
Serum cytoglobin was significantly more effective and higher in 
patients with early-onset preeclampsia (EO-PE) and slow onset of 
preeclampsia (LOPE), compared with healthy pregnant women [30]. 
Uric acid with proteinuria can identify perinatal risk with high risk with 
gestational hypertension in women [31]. However, serum uric acid will 
increase after presentation of clinical symptoms of PE and cannot be a 
biomarker [32].
ROLE OF HEAT SHOCK PROTEIN (HSP) IN PREECLAMPSIA
HSPs play an important role in the maintenance of cellular homeostasis, 
where these proteins constitute about 5–10% of the total protein of all 
normal cells and mediate protein assembly and proper intracellular 
localization [33]. HSP20 is widely expressed under normal physiological 
conditions and plays an important role in the dilation of blood vessels 
and the collection of platelet suppression and as a marker for predicting 
the onset of PE or severity with decline in the chorionic plate resistance 
artery and in serum female PE [34]. HSP27 was found to be a translation 
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initiation and signal transducer, transcription activator-3 (STAT3) level 
administrator, because HSP27 is a key protein during the development 
of placenta and differentiation of trophoblast cells, STAT3, and 
eukaryotic initiation factor of eukaryotic 4E is involved in regulating 
the differentiation/migration of extracellular trophoblast cells [35]. 
Upregulation of Hsp27 is a common phenomenon in pregnancy that is 
affected with PTB and PPROM. Downregulation of HSP70 and HSPBP1 
also represents the unique feature of PPROM [36]. HSPs can be induced 
in cells as a protective mechanism and play a role in PE [37].
HSP70 is one factor that can mediate the effects of cytoprotective, 
antiapoptotic, and immune regulation, HSP70 serum concentrations 
were significantly higher in patients with PE than in the control group. 
Therefore, HSP70 may be identified as a diagnostic factor [38]. Serum 
HSP70 plays a protective role in tissue damage and a higher liver 
stiffness value in patients with biliary atresia, so serum HSP70 and 
liver stiffness may serve as a non-invasive parameter [39]. HIF-1α and 
HSP70 have a close relationship with the origin and development of 
the disease for the diagnosis and treatment of the disease [40]. HSP70 
and proliferation are associated with trophoblast cells and decidual 
cells in exhibiting highly proliferative activity, as demonstrated by 
PCNA immunohistochemistry, at the mid-gestational stage. However, 
the difference is the decrease in the percentage of PCNA-positive 
cells observed in the final stages [41]. HSP70s also protect cells from 
the proteotoxic stress associated with abnormal rapid proliferation, 
suppresses cell aging and provides resistance to stress-induced 
apoptosis including protection against cytostatic, drugs, and radiation 
therapy [42]. Recent data also showed that serum Hsp70 (HSPA1A) 
levels are elevated in diabetes mellitus types 1 and 2. However, further 
research is needed to determine whether Hsp70 is a cause in the 
pathogenesis of gestational diabetes [43].
ROLE OF IMMUNOLOGY CELLS IN PE
The immunologic mechanism also plays an important role in the 
pathophysiology of PE. Helper T-Cell 17 (Th17) as a new subset of 
effector T-cells and plays an important role in host defense in extracell 
pathogens, autoimmune, and inflammatory in PE such as recurrent 
spontaneous abortion (RSA) [44]. T regulatory cells (Treg cells, FoxP3 +) 
suppresses cytotoxic T-cells (CD8 +) and responds to natural killer cells 
(NK) and increases immunological tolerance in the fetus [45]. Dendritic 
cells (DC) are also involved in the immune system, which regulates 
differentiation of Th17 and regulatory T-cells (Treg) participating in PE 
and RSA, but there is still a shortage in the intrahepatic cholesterol study 
of pregnancy (ICP) [46]. IL-17 and podocyte levels also had a positive 
association in serum and overreaction of microRNA-155 (miR-155) in 
PE patients, thus results in increased IL-17 production by CD4 + T-cells 
in vitro, and decreased nephrin expression in podocytes and apoptotic 
processes of podocytes [47]. In addition, high red cell distribution 
width can be a promising marker to predict low CD4 cell counts in 
HIV-positive reproductive women in antiretroviral therapy in PE 
women [48]. The effects of adiponectin on the cardiovascular system in 
hypertensive patients are believed to be partially mediated by activation 
of 5’ active adenosine monophosphate protein kinase and pathway 
cyclooxygenase-2, reduces endothelial cell apoptosis, promotes the 
production of nitric oxide, decreased activity in tumor necrosis factor-
alpha (TNF-α), and prevented atherosclerotic proliferation and smooth 
muscle cell migration [49]. In addition, there is a consensus strategy 
to improve early detection and enrichment of pathogenic genes in PE 
such as HSP90, PAK2, CD247, and others, included in the first 1% of the 
prioritized list, so it needs to be explored further on the pathogenesis 
of PE through an experimental approach [50]. Activation of endothelial 
antibodies is also a marker of cardiovascular system dysfunction and 
endothelial dysfunction as well as severe pathology, with multiple 
organ failure manifestations, which is evidence of the relevance of this 
area of research to a large number of patients [51]. Detyrosination and 
tyrosination of tubulin are also important for the stability and dynamics 
of microtubules and significantly reduces the level of detyr-tubulin in the 
placental biopsy, placental angiogenesis damage, and vascularization in 
cases of PE [52]. The implantation site macrophages comprised about 
20% of the population leukocytes, and as a major mediator thereby 
increasing the expression of M-CSF, pro-inflammatory cytokines, IL-1b, 
or TNF-α, mainly through the NF-kB pathway signal to increase M-CSF 
expression in FTDCs, leading to M2 polarization of macrophages, and 
the phagocytic capacity of M2 macrophages is consistently improved, 
possibly through downregulation of SIRPa [53]. In gene levels, based 
on expression of 15 genes from C19MC, microRNAs (miR-512-5p, miR-
515-5p, miR-516-5p, miR-517-5p, miR-518b, miR-518f-5p, miR-519a, 
miR-519d, miR-519e-5p, miR-520a-5p, miR-520h, miR-524-5p, miR-
525, miR-526a, and miR-526b) were assessed in the placental tissue, 
miR-519a was found to be associated with severe PE. The longer the 
pregnancy-related disorder progresses, the wider the regulation of 
microRNAs decreases (miR-515-5p, miR-518b, miR-518f-5p, miR-
519d, and miR-520h). Downregulation of some C19MC microRNAs is a 
common phenomenon that is shared between GH, PE, and FGR. On the 
other hand, some C19MC microRNAs are only derived only on PE [54]. 
In Egyptian women, There is a significant association between VEGF 
C 405 G and VEGF C 2578 A gene polymorphisms. Thus, the screening 
for PE mutations for all Egyptian pregnant women in order to set up 
an appropriate method of prophylaxis against these pre-eclamptic 
disorders [55].
APOPTOSIS OF PLACENTA IN PE
The main cause of PE is the placenta in the presence of trophoblast 
tissue that can cause apoptosis [56]. In addition, toxic effects of carbon 
monoxide from tobacco can damage mitochondria in pregnant smokers, 
resulting in reduced birth weight [57]. Apoptosis in the placenta was 
found to increase in PE and associated with the activation of caspase-8 
on the extrinsic pathway, then caspase-3 activation [58]. FasL expression 
was significantly less and Bcl-2 expression was significantly greater 
in villous trophoblasts due to increased apoptosis and the formation 
of a synthetic node combination by reducing FasL expression may be 
involved in the pathophysiology of the mechanism of PE [59]. Increased 
apoptotic signaling leads to reduced nutrient transport capacity, 
which triggers the release of vascular factors in the placenta, maternal 
vascular produce response because the fetus must adapt to changes in 
the intrauterine environment, and this adaptation increases the risk 
of disease in offspring [60]. A danger signal in preeclampsia, that is, 
a high mobility group box 1 that participates in various inflammatory 
processes and processes in the placenta [61]. Fetal developmental 
disorders cause antioxidant enzymes not able to cope with increased 
levels of oxidative stress, resulting in epigenetic changes at the specific 
level of genes to transcribe antioxidant enzymes [62]. Telocytes which 
are a new type of stromal cells associated with signal transduction 
mechanisms in the regulation of fetal blood vessels in placenta PE can 
be damaged by oxidative stress and placental apoptosis of endothelial 
cells, and trophoblast cells [63]. For strong antioxidants, melatonin 
plus indoleamine has utility in the treatment of PE, intrauterine growth 
restriction, placental and fetal/reperfusion ischemia, etc [64].
Maintain a physiological balance between the proliferation of 
cytotrophoblast (CTB) with the placental vein and apoptosis is very 
important because of increased oxidative stress and apoptosis in 
the pathological placenta is not balanced [65]. Impaired nitric oxide 
pathways and excessive stress on endoplasmic reticulum (ER) have 
been observed in the stress response and iNOS that may be associated 
with increased apoptosis in the placenta of PE patients [66]. In 
HELLP syndrome, there is an increase in apoptosis, proliferation, and 
FAS ligand expression in the placenta compared with placentae PE 
and normal pregnancy [67]. One of the placental factors involved in 
triggering PE is trophoblast debris, which can pass the pathogen signals 
from the placenta to endothelial cells, where trophoblastic debris from 
the placenta of PE leads to endothelial cell activation [68]. Observation 
of trophoblast cells in the placenta can be done with Formalin-fixed 
paraffin-embedded (FFPE), observed with immunohistochemistry and 
calcyclin, resulting in an increase in trophoblast cells in the placenta 
PE compared with normal trophoblast cells [69]. To determine cell 
apoptosis or cell fragments derived from CTB or syncytiotrophoblast, 
use E-cadherin staining together with markers for apoptosis [70]. 
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During pregnancy, the subset of placental CTB differentiates into 
cells that aggressively invade the uterus and blood vessels [71]. The 
vasculosyncytial  membrane (VSM) is a fetomaternal exchange when 
syncytiotrophoblast surrounds the terminal villi and makes close 
contact with the capillaries. The inverse relationship between the VSM 
and hypoxia in the fetus disrupts the syncretial PE [72]. Increased 
apoptosis, CTB necrosis, and syncytiotrophoblast may compromise 
placental function, including nutrient transport and cause increased 
shedding syncytiotrophoblast extracellular vesicles (STBEV) in PE, 
but relaxin (pregnancy hormone) may improve [73]. The release 
of extracellular vesicles (EVs) by syncytiotrophoblast (STB) is an 
important mechanism, in which placental signaling to the mother is 
important in the formation, maintenance of a healthy pregnancy and 
provides a real-time reading of placental health [74]. After delivery 
of the placenta, the rapidly restored state is caused by growth factors 
vascular endothelial signals which are impaired [75,76]. However, with 
the administration of 1,25-dihydroxyvitamin D (1,25(OH)2D) during 
pregnancy reduces the adverse outcome of PE [77]. Pomegranate juice 
can reduced oxidative stress on the placenta in vivo and in vitro induced 
by stimuli from trophoblast women PE [78]. A decreased enzymatic 
antioxidant capacity and increased oxidation in placental tissue from 
PE women, which may contribute to the pathogenesis of this complex 
disorder [79]. In the study, the presence of concentration nitric oxide 
in placenta  PE was higher significantly than normal placenta. Hence, 
there was no significant difference caused by decrease markedly of ROS 
production [80].
The development of PE induced by apoptosis of trophoblast cells 
may decrease miR-34a which is an effective strategy for increasing 
apoptosis in the trophoblast cells [81]. Apoptosis in trophoblasts also 
invades and overhauls the uterine spiral artery in the signal system 
of epidermal growth factor signaling that regulates differentiation 
in trophoblasts [82]. The Wnt signaling path plays an important role 
in regulating trophoblast functions. Wnt signaling pathways were 
detected in the placenta in the third trimester, decreased placental 
expression of Wnt2, and increased placental expression of secreted 
frizzled-related protein 4 (SFRP4) [83]. Signaling is the function of the 
Wnt/β-catenin pathway in the placenta of PE is significantly inhibited, 
due to oxidative stress and apoptosis [84]. Excessive activation of 
the terminal pathway is associated with fetal growth restriction in 
preeclamptic women in the third trimester of human pregnancy [85]. 
In apoptosis, protein P53 is regulated in HUVECs which triggers the 
capture of G1, then P21 expression increases, decreases the regulation 
of cyclin E expression, and CDK2-cyclin E complex. Increased regulation 
of P53 also activates the Bax gene, suppresses the Bcl-2 gene, BIRC5 
resulting increased Bax/Bcl-2 ratio, and then activated caspase cascade, 
eventually apoptosis [86]. At the moment advances in biomarkers, 
therapies and genetic profiles are becoming an effective treatment in 
PE [87]. Potential biomarkers of this disease, such as activin A may 
lead to increased nodal expression and further increase Nodal/ALK7 
signaling to induce apoptosis of the trophoblastic cells [88]. Low-dose 
aspirin is also widely used in preventing PE and reduces apoptosis 
caused by H2O reduces the ability of caspase-3 activation and TNF-α 
expression levels in PE [58]. New mitochondrial proteins such as 
mitofusin-2 (Mfn2) in the placenta are detected by qRT-PCR, indicating 
mitochondrial dysfunction, decreasing trophoblast cell viability, and 
contributing to the multifactorial pathogen mechanism of PE [89]. 
The important role of mitochondrial activity changes in the adaptive 
response to the development of PE, due to increased OPA1 mRNA and 
protein expression in the placenta [90]. Potential genes such as STOX1 
and ACVR2A were also identified determining their causality in PE 
disorders [91]. In PE, male fetal placenta is associated with much higher 
expression of inflammation, hypoxia, and apoptosis than female fetal 
placenta but reduces the expression of pro-angiogenic markers [92].
Complementary system activation is also involved in PE pathologic 
processes, such as complementary 5a (C5a) that plays an important 
role in placental abruption, regulate migration, and trophoblast 
angiogenesis and is also associated with maternal blood pressure 
and arterial stiffness [93]. Calreticulin (CRT) is also an important ER 
residental protein (ER) that participates in the intracellular regulation 
of Ca2 homeostasis, cell adhesion, and cell apoptosis [94]. Shedding of 
syncytiotrophoblast microparticles from the placenta to maternal blood 
occurs under normal circumstances of pregnancy and is enhanced 
during PE [95]. Placental on syncytiotrophoblast microvesicles 
(STBMs) in the maternal circulation during normal pregnancy is 
significant in PE and STBM proteins are involved in immune responses, 
coagulation, oxidative stress, apoptosis, and lipid metabolism [96]. 
Injection of light into pregnant mice also induces placental apoptosis, 
small fetuses, PE, hypertension, and proteinuria where light functioning 
through 2 receptors induces the secretion of fms-like tyrosine kinase-1 
and endothelin-1, 2 pathogenic factors in PE [97].
PLACENTAL MICRORNA EXPRESSION IN PE
MicroRNAs (miRNAs) have emerged as major regulators in the 
stability of gene expression involved in cell proliferation and apoptosis, 
whereas their expression may be altered in association with a variety 
of pathological disorders, such as in PE and preterm delivery [98]. 
There are Target genes of miRNAs,  that participate in organ/system 
development (cardiovascular and reproductive system), immunologic 
dysfunction, cell adhesion, cell cycle, and signaling in PE [99]. MicroRNA 
(miRNA) is a small non-coding RNA which regulates gene expression 
through mRNA degradation and translational suppression. As a 
result, the expression of miR-210 is regulated in the placenta causing 
repression. Thus, miR-210 has a major effect on placental mitochondria 
[100]. Three miRNAs (miR-17, -20a, and -20b) increased significantly in 
PE compared with normal placenta [101].
HEPATIC DISEASE IN PE
Liver disorders of PE may increased liver enzymes, low platelets 
(HELLP), acute fatty liver, hyperemesis gravidarum, intrahepatic 
cholestasis, and autoimmune liver [102]. Atypical hemolytic uremic 
syndrome  in a woman pregnant who was given the diagnosis of 
gestational hypertension, and hemolysis, elevated liver enzymes, and 
low platelet count (HELLP) also occurs in preeclampsia [103]. In terms 
of age, elderly gravidae (age ≥35 years) showed higher levels of urea and 
uric acid when compared with women <35 years, so increased age may 
increase the risk of impaired kidney and liver function [102]. Based on 
the Fibroscan results for 1–7 days postpartum, fibrosis was significantly 
higher in PE women (although within the normal range [104]. Most of 
the causes of liver function impairment during the third trimester were 
hypertension, which induced pregnancy with HELLP syndrome (37%), 
acute fatty liver pregnancy (37%), and viral hepatitis (20%) [105,106]. 
In PE disorders, non-hypoxia is also a pathway that may be involved in 
angiogenic changes and abnormal metabolism in PE because defects in 
angiogenesis and mitochondrial function in the placenta contribute to the 
pathogenesis of PE, but the upstream regulator of this path is unknown 
[107]. Trophoblastic mitochondrial damage is a common terminal path, 
as it may cause different changes in lipid metabolism [108]. LDL-c 
and HDL-c isolated from PE indicating oxidative damage to lipids and 
proteins. Antioxidants are needed to reduce oxidative stress and induce 
damage in the vascular endothelium [109]. Selenium is an important 
constituent that acts as an antioxidant and has some possible metabolic 
function in terms of treating PE with a certain concentration [110]. 
Extra Virgin Olive Oil (EVOO), in the form of extra virgin, contains a rich 
antioxidant tocopherol (Vitamin E) capable of controlling the induction 
of HSP70 serum levels are not excessive, so the process of apoptosis 
does not occur excessively, especially PE [111]. A significant effect of 
EVOO on TGF-β expression in placenta and there was a positive and 
strong relationship (r=0.494) as well as a very significant relationship 
(p<0.01) between TGF-β and the serum MDA [112].
On multivariate analysis, women with abnormal alanine aminotransferase 
level before pregnancy had a 1.21-fold increased risk of developing 
preeclampsia than those with normal alanine aminotransferase level 
before pregnancy [113]. Patients with intrahepatic cholestasis of 
pregnancy and elevated levels of alanine aminotransferase should be 
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followed up for perinatal normal results, so as to safeguard maternal 
and fetal safety [114]. Serum levels of liver fatty acid-binding proteins 
(LFABP) in PE women, correlated with the severity of PE, may be used 
to confirm the diagnosis [115]. HELLP syndrome can be measured by 
elastosonography acoustic radiation force impulse (ARFI) [116]. For 
the diagnosis of HELLP syndrome, elevated levels of ET-1, M30, and 
Angs-1 and -2 appear as promising apoptotic-associated biomarkers 
where serum M30 levels have the benefit of being the most promising 
test for predictive or differential diagnosis of HELLP syndrome in PE 
patients [117]. D-dimers can also be as biomarkers in fibrin formation 
and degradation where levels were significantly increased in Sudanese 
women with PE, with hemostatic abnormalities [118].
Women who have non-alcoholic fatty liver (NAFLD) before delivery of 
the fetus, increase the risk of pregnancy adversely independently of 
body mass index and diabetes and should be monitored carefully during 
antenatal care [119]. Prenatal serum bilirubin, plasma fibrinogen 
levels, and platelet counts are the predictors of postpartum recovery 
in the acute fatty liver of pregnancy (AFLP) [120]. Chronic alcohol 
consumption without AFLD can lead to significant circulation increases, 
as an inflammatory marker and may result in downregulation of 
oxidative stress production [121]. In addition to acute fatty liver of 
pregnancy (AFLP), intrahepatic cholestasis of pregnancy (ICP) is the 
most common liver disease in pregnancy that causes hepatobiliary 
and immune-mediated cancers and cardiovascular disease [122]. In 
Western India, Hepatitis E is the most common cause of liver disease in 
pregnant women resulting in maternal mortality, predicted with high 
MELD scores [123]. Two rare causes of hepatitis, especially fulminan 
(rare complications of the herpes simplex virus) such as HSV-1 and 
HSV 2 are comorbid in the same patient [124]. Pregnancy in women 
with cirrhosis of the liver, portal hypertension, or esophageal varices 
leads to worse pregnancy and may warrant closer antenatal monitoring 
and patient counseling [125]. Different levels of bile acid and carnitine 
circulation can be altered in patients with primary biliary cirrhosis 
(PBC) as potential biomarkers [126]. The circulating levels of different 
bile acids and carnitines can be changed in patients with primary 
biliary. Liver infarction is dangerous and  complications associated with 
hemolysis, elevated liver enzymes, and ow platelet syndrome (HELLP), 
may cause cardiac arrest and fulminant liver failure [127]. Due to 
advances in obstetric and transplant medications, women with a history 
of liver transplants can have successful pregnancies. The transplanting 
process should have a relationship with maternal and fetal levels of high 
morbidity [128]. Liver transplantation also restores sexual function and 
fertility as early as, a few months after transplantation [129].
KIDNEY DISEASE IN PE
Renal function monitoring appears to be relevant for PE, especially 
since albuminuria should be evaluated in postpartum and are classified 
at high risk for impaired renal function [130]. Podocytes play a role 
in the development of kidney damage and prevention of long-term 
complications of PE [131,132]. The depletion of podocytes in the kidneys 
is associated with end-stage renal disease (ESKD). PE may also increase 
the risk of future ESKD [133]. The depletion of podocytes may also affect 
individuals with the APOL1 genotype against the risk of kidney disease 
in blacks [134]. Persistent proteinuria is the most important predictor of 
renal disease and sustained proteinuria, persistent hematuria, or renal 
function disorder after the postpartum period [135]. Proteinuria also 
results in the loss of fetuin-A, resulting in low molecular weight [136]. 
PE also causes transient renal disease, characterized by hypertension 
and proteinuria then induced hypertensive pregnancy (PIH) and 
HELLP syndrome [137]. In PE, deteriorating arterial gradients and 
hemodynamic venous abnormalities of gestational hypertension 
(GH) linearly correlate between proteinuria and renal interlobar vein 
impedance index (RIVI [138]). Chronic pregnancy renal disease (CKD) 
has a high risk and to evaluate renal function during pregnancy after 
renal transplantation can lead to higher preterm prevalence and a worse 
neonatal prognosis [139,140] and until now there have been no reports 
of maternal deaths, childbirths, or neonatal deaths in renal donors. 
However, PE is more common in renal donors [141]. Acute kidney 
injury (AKI) is a serious problem during pregnancy and understanding 
the physiological kidney adaptation during pregnancy is essential for 
early detection, diagnosis, and appropriate management to prevent 
obstetric complications [142]. In pregnant women with type I diabetes 
mellitus (T1DM) at increased PE risk, urine albumin examination 
should be performed to prevent kidney complications [143]. Giving 
serum containing gelocalin-associated gelatinase (NGAL) can be 
correlated with renal inflammation in severe PE [144]. Tempol, a 
mimetic dismutase-antioxidant drug has been shown to weaken radical 
damage, exert beneficial effects on animal models of oxidative stress and 
hypertension, against chronic ischemic renal injury, and prevent renal 
dysfunction through antioxidants, vasodilators, and antihypertensive 
[145]. In addition, the plant-based diet should be limited, especially 
those containing proteins in PE patients, as it can control proteinuria 
in pregnant CKD women with segmental focal glomerulosclerosis [146].
PE is also associated with hypercoagulability, endothelial dysfunction, 
and inflammation, resulting in microparticles (MPs) in which 
microparticles of platelets (PMPs), endothelial cells (EMPs), and 
leukocytes (LMPs) which are a method of knowing the presence 
of endothelial dysfunction and inflammation involved in the 
pathogenesis of PE [147]. Glomerular damage kidneys are common in 
PE and can be identified with tubular channels such as 1-microglobulin 
(A1M), retinol-binding protein (RBP), molecule-1 (KIM1), C5b-9, 
metalloproteinase-2 (TIMP-2), and insulin growth factors binding 
protein-7 (IGFBP-7) [148]. Metalloproteinase-2 and IL-18 tissue 
inhibitors show that the kidneys have an increased inflammatory 
response during pregnancy and tubular epithelial tubular injury [149]. 
Biomarkers have also been found to differentiate CDK and PE, where 
the sFlt-1 rate increases significantly compared to CKD and control 
[150]. Levels of serum cystatin C, urine RBP, urine NGAL, and urine 
KIM-1 in the PE group were higher than in the normal pregnancy group. 
When four biomarkers are combined, the sensitivity and specificity 
is 100% and 98.20% respectively. Hence, urine KIM-1 biomarkers 
are the most common for kidney injury in PE [151]. Low-molecular-
weight heparin (LMWH) can also control the condition of PE, protect 
kidney function, improve to fetal health, and protect kidney function by 
inhibiting apoptosis [152]. Nephrin relative administration in patients 
increased after LMWH intervention and accompanied by decreased 
proteinuria. Glomerular nephrin expression in L-NAME induced 
preeclampsia significantly decreased and down-regulation of nephrin 
is involved in L-NAME induced proteinuria [153]. Molecularly recently, 
DNA-containing mitochondria with unmethylated CpG motifs and 
formyl peptides have been shown to damage the associated molecular 
pattern (DAMP) and induce immune responses and clinical cell injury 
mtDAMPs that cause increased urine protein in mice, resulting in 
damage to proteinuria and kidney [154].
CONCLUSION
Proteinuria, blood pressure, dipstick test, RAS, adipsin, CCR, ACR, 
and uric acid are biomarkers in PE diagnosis. Increased apoptosis, 
CTB necrosis, and syncytiotrophoblast may compromise placental 
function, including nutrient transport and cause increased shedding of 
extracellular vesicle syncytiotrophoblast (STBEV) so that compounds 
and antioxidant and antiapoptotic drugs are needed.MicroRNA in PE 
as major regulators in the stability of gene expression involved in cell 
proliferation and apoptosis. Liver and kidney disease in PE women 
have a high risk of pregnancy disorder, although until now no reports of 
maternal death, the birth of premature infants or neonatal death.
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